logo-loader
viewMaxCyte Inc

MaxCyte study results point to the effectiveness of its technology

The data appeared in Science Translational Medicine and resulted from a collaboration with the National Institute of Allergy and Infectious Diseases in the US.

shutterstock_234586750.jpg
The results were encouraging for the company

MaxCyte Inc (LON:MXCT) said the results of a pre-clinical study published in a leading journal showed the company’s technology is effective in correcting for genetic mutations.

The data appeared in Science Translational Medicine and resulted from a collaboration with the National Institute of Allergy and Infectious Diseases in the US.

Researchers used MaxCyte’s Flow Electroporation Technology and were able to correct mutation in the CYBB gene.

"We are very encouraged by the preclinical data obtained in this study, which showed the effectiveness of [our] proprietary, high-performance technology to correct for genetic mutations, especially in cases where traditional viral vector-based gene insertion methods have not been effective," said the company’s chief scientific officer, Madhusudan Peshwa.

"This study also demonstrates the commitment of MaxCyte to fostering development of novel cell therapies and supporting our partners' use of our delivery platform. MaxCyte invests early in translational development of non-virally engineered and ex vivo gene-edited cell therapy products.”

Quick facts: MaxCyte Inc

Price: 112 GBX

AIM:MXCT
Market: AIM
Market Cap: £64.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read